SCHEMBL6476886

SCHEMBL6476886

CC(C)(C)OC(=O)NC(CSCC1CCCCC1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.54
CTSK P43235 2/20 0.54
PPARG P37231 9/20 0.51
PPARA Q07869 9/20 0.51
PPARD Q03181 2/20 0.49
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CACNA1B Q00975 2/20 0.44
METAP2 P50579 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477556 1.00 CTSS (0.54) CTSSCTSKPPARGPPARAPPARD
SCHEMBL4845165 1.00 CTSS (0.54) CTSSCTSKPPARGPPARAPPARD
SCHEMBL3619211 0.93 PPARG (0.54) CTSSCTSKPPARGPPARAPPARD
SCHEMBL6480048 0.84 CTSS (0.46) CTSSCTSKPPARGPPARAHDAC4
SCHEMBL16945 0.82 CTSK (0.70) CTSSCTSKPPARGPPARAHDAC4
SCHEMBL9742302 0.82 CTSK (0.70) CTSSCTSKPPARGPPARAHDAC4
SCHEMBL21427213 0.82 CTSK (0.70) CTSSCTSKPPARGPPARAHDAC4
SCHEMBL21427220 0.82 CTSK (0.70) CTSSCTSKPPARGPPARAHDAC4
SCHEMBL8283416 0.82 CTSK (0.70) CTSSCTSKPPARGPPARAHDAC4
SCHEMBL9742291 0.82 CTSK (0.70) CTSSCTSKPPARGPPARAHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP CTSS 1777/4885CTSK 2334/4885PPARG 4149/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP CTSS 1777/4885CTSK 2334/4885PPARG 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.